Atty. Dkt. No. 065691-0434 AP28 Regid PGT/PFO 08 FEB 2006

IN THE UNITED STATES PATENT AN D TRADEMARK OFFICE

Applicant:

Alain MOUSSY et al.

Title:

USE OF C-KIT INHIBITORS FOR TREATING TYPE II DIABETES

Int'l. Appl. No.:

PCT/IB2004/002934

Int'l. Filing Date:

8/16/2004

Examiner:

Unassigned

Art Unit:

Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

10/567557

Atty. Dkt. No. 065691-0434 2006

RELEVANCE OF EACH DOCUMENT

The documents being cited in the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of the documents considered relevant by the examiner. A copy of the cited references listed in the Search Report are not being submitted herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date & Fobruary 2006

FOLEY & LARDNER LLP Customer Number: 22428

Telephone:

(202) 672-5569

Facsimile:

(202) 672-5399

Stephen B. Maebius

Attorney for Applicant Registration No. 35,264

IAP20 Res'd PCT/PTO 08 FEB. FED PO SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1	449B/PT	0		Complete if Knows / 567557		
	INFORMATION DIS	CLOSUR	E	Application Number	Unassigned .		
	STATEMENT BY AF	PPLICAN	T	Filing Date	February 8, 2006		
	Data Culturittadı Faha	9 3	2006	First Named Inventor	Alain MOUSSY		
	Date Submitted: Febru	Jai y O, Z	.000	Group Art Unit	Unassigned		
	(use as many sheets a	s neces	sary)	Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	065691-0434		

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant	
	No.1	Number	Kind Code ² (<i>if</i> known)	Document	Cited Document MM-DD-YYYY	Figures Appear	
	-						

Examiner		Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials*		Office	3 Number ⁴	Kind Code ⁵ (<i>if known</i>)	Applicant of Cited Documents	MM-DD-YYYY Passages or Relev	Passages or Relevant Figures Appear	Te Te
/KW/	A1	EP	0 934 931 A		SUGEN INC.	8/11/1999		
8	A2	WO	01/64200 A		Robert Charles ATKINS et al.	9/7/2001		
	A3	WO	2004/105763 A		Robert Per HAEGERKVIST et al.	12/9/2004		
\	A4	wo	2004/014903 A		Marco CIUFOLINI et al.	2/19/2004		
- W	A5	WO	2004/098612 A		Alain MOUSSY et al.	11/18/2004		
/KW/	A6	wo	2004/076693 A		Alain MOUSSY et al.	9/10/2004		

	NON PATENT LITERATURE DOCUMENTS	•				
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					
A7	MAY et al., "INDOLINONE DERIVATIVES INHIBIT CONSTITUTIVELY ACTIVATED KIT MUTANTS AND KILL NEOPLASTIC MAST CELLS", Journal of Investigative Dermatology, New York, NY US, Vol. 114, No. 2, February 2001, pp. 392-394.					
A8	Y. ZERMATI et al., "Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated neoplasms", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 22, 2003, pp. 660-664.					
	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. A7 MAY et al., "INDOLINONE DERIVATIVES INHIBIT CONSTITUTIVELY ACTIVATED KIT MUTANTS AND KILL NEOPLASTIC MAST CELLS", Journal of Investigative Dermatology, New York, NY US, Vol. 114, No. 2, February 2001, pp. 392-394. A8 Y. ZERMATI et al., "Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated neoplasms", ONCOGENE,				

Examiner Signature	/Kevin Weddington/ (08/15/2008)	Date Considered	08/15/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 20313-1450. Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.